Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Fagron    FAGR   BE0003874915

FAGRON

(FAGR)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
06/18/2019 06/19/2019 06/20/2019 06/21/2019 06/24/2019 Date
17.68(c) 18.06(c) 17.94(c) 17.79(c) 17.93 Last
138 639 141 934 118 307 245 429 93 661 Volume
+2.67% +2.15% -0.66% -0.84% +0.79% Change
More quotes
Financials (EUR)
Sales 2019 522 M
EBIT 2019 92,9 M
Net income 2019 60,7 M
Debt 2019 213 M
Yield 2019 0,78%
Sales 2020 571 M
EBIT 2020 109 M
Net income 2020 73,9 M
Debt 2020 159 M
Yield 2020 0,94%
P/E ratio 2019 20,63
P/E ratio 2020 17,02
EV / Sales2019 2,86x
EV / Sales2020 2,52x
Capitalization 1 278 M
More Financials
Company
Fagron specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. The group ensures the sale of pharmaceutical formulas and raw materials, provides third-party pharmaceutical compounding services to... 
Sector
Pharmaceuticals
Calendar
08/05 | 01:00amEarnings Release
More about the company
Surperformance© ratings of Fagron
Trading Rating : Investor Rating :
More Ratings
Latest news on FAGRON
05/16FAGRON : Ex-dividend day for final dividend
FA
05/15FAGRON NV : - Fagron shareholders approve all proposed resolutions
AQ
05/15FAGRON NV : Fagron shareholders approve all proposed resolutions
AQ
05/14FAGRON NV : Fagron enters Mexican market with acquisition of Cedrosa
AQ
05/14FAGRON NV : Fagron shareholders approve all proposed resolutions
GL
05/13FAGRON NV : Fagron enters Mexican market with acquisition of Cedrosa
AQ
05/13FAGRON NV : Fagron enters Mexican market with acquisition of Cedrosa
GL
04/15FAGRON : continued strong turnover growth in first quarter 2019
AQ
04/12FAGRON : Convocation annual general meeting and extraordinary meeting
GL
04/12FAGRON : continued strong turnover growth in first quarter 2019
GL
More news
Analyst Recommendations on FAGRON
More recommendations
Sector news : Pharmaceuticals - NEC
12:05pBRISTOL MYERS SQUIBB : Myers' Celgene Deal Can Still Be a Winner -- Heard on the..
DJ
11:55aBRISTOL MYERS SQUIBB : Myers plans to divest Celgene's psoriasis drug
RE
11:53aBRISTOL MYERS SQUIBB : Myers plans to divest Celgene's psoriasis drug, shares sl..
RE
09:24aAbbVie Says FDA Lifts Partial Hold on Phase 3 Trial
DJ
08:39aBRISTOL MYERS SQUIBB : Myers to Shed Otezla, Carving Path for Celgene Deal
DJ
More sector news : Pharmaceuticals - NEC
Chart FAGRON
Duration : Period :
Fagron Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FAGRON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 19,1 €
Spread / Average Target 7,3%
EPS Revisions
Managers
NameTitle
Rafael Padilla Papaceit Chief Executive Officer & Director
Koen Hoffman Chairman
Karin de Jong Chief Financial Officer & Executive Director
Giulia van Waeyenberge Independent Director
Frank Jozef Paul Vlayen Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
FAGRON24.58%1 386
JOHNSON & JOHNSON10.10%348 981
PFIZER0.05%233 072
ROCHE HOLDING LTD.13.87%227 848
NOVARTIS21.31%220 893
MERCK AND COMPANY10.68%206 641